Enhanced O-GlcNAcylation Mediates Cytoprotection under Proteasome Impairment by Promoting Proteasome Turnover in Cancer Cells

The proteasome is a therapeutic target in cancer, but resistance to proteasome inhibitors often develops owing to the induction of compensatory pathways. Through a genome-wide siRNA screen combined with RNA sequencing analysis, we identified hexokinase and downstream O-GlcNAcylation as cell survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Eiichi, Okuno, Shota, Hirayama, Shoshiro, Arata, Yoshiyuki, Goto, Tsuyoshi, Kosako, Hidetaka, Hamazaki, Jun, Murata, Shigeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338785/
https://www.ncbi.nlm.nih.gov/pubmed/32634741
http://dx.doi.org/10.1016/j.isci.2020.101299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338785/
https://www.ncbi.nlm.nih.gov/pubmed/32634741
http://dx.doi.org/10.1016/j.isci.2020.101299

Ejemplares similares